Background/Objectives: Discovered in 2019, COVID-19 spread rapidly worldwide, leading from mild forms of the disease to critical forms or death, predominantly among vulnerable patients. Severity scores help clinicians in stratifying the risk of complications and death among patients diagnosed with SARS-CoV-2 infection. Methods: This study aims to identify the severity scores used in this type of infection, while bibliometric analysis carried out provided a comprehensive overview of global research patterns, trends, and cooperation in scientific literature on the chosen topic. Results: We conducted a literature screening to identify severity scores used in SARS-CoV-2 infection. Scores including CURB-54, COVID-GRAM, NEWS, APACHE II, SOFA, qSOFA, CALL, MuLBSTA, ISARIC 4C, and PADUA were identified with different performance indices. Conclusions: There were different results obtained depending on the geographical area of applicability, patient groups analyzed, and individual patient characteristics.

Background: The elderly remain a population group at risk of developing severe forms of SARS-CoV-2 infection. Age and the prevalence of comorbidities are important risk factors for mortality related to COVID-19. Severity scores enhance medical practice, proving to be useful tools in predicting mortality. Objectives: The purpose of this study is to assess the predictive accuracy of the CURB-65, Pneumonia Severity Index, MuLBSTA, COVID-GRAM and PADUA scores in patients over 70 years of age diagnosed with SARS-CoV-2 infection. Methods: We performed a retrospective study between June 2023 and December 2024, analyzing demographic data, vaccination status, comorbidities, discharge status, and computed the five scores. Results: A total of 173 patients aged over 70 years old were included in the study. Among them, 56.06% were male with a median age of 79.72 ± 6.55. Many patients had at least one comorbidity (93.06), among which hypertension (67.63%), neurological pathology (41.61%), diabetes mellitus (28.90%) and obesity (28.32%). Tumor pathology was associated with an increased risk of death. Admission to the intensive care unit and mechanical ventilation were also risk factors for increased mortality in the study population. The area under the ROC curve (AUC) of the scores (in descending order) was: 0.914 for PADUA, 0.854 for MuLBSTA, 0.831 for PSI, 0.719 for CURB-65 and 0.703 for COVID-GRAM. Conclusions: All the severity scores used were significantly higher in the non-survivor group, with PSI, MuLBSTA, and PADUA scores revealing acceptable prediction ability for mortality.

Background: Renal failure in COVID-19 patients is reportedly related to multiple factors such as a direct SARS-CoV-2 cytopathic effect, cytokine storm, the association of pulmonary and/or cardiovascular lesions, the presence of thrombotic microangiopathy, endothelial damage, or the use of potentially nephrotoxic medications. Methods: We retrospectively analyzed 466 cases of SARS-CoV-2 infection, comparing 233 patients with acute kidney injury (AKI) with 233 patients without AKI in terms of their demographic characteristics, comorbidities, clinical background, laboratory investigations, time of AKI onset, therapy, and outcomes after using univariate analysis and a CART decision-tree approach. The latter was constructed in a reverse manner, starting from the top with the root and branching out until the splitting ceased, interconnecting all the predictors to predict the overall outcome (AKI vs. non-AKI). Results: There was a statistically significant difference between the clinical form distribution in the two groups, with fewer mild (2 vs. 5) and moderate (54 vs. 133) cases in the AKI group than in the non-AKI group and more severe and critical patients in the AKI cohort (116 vs. 92 and 60 vs. 3). There were four deaths (1.71%) in the non-AKI group and 120 deaths in the AKI group (51.5%) (p-value < 0.001). We noted statistically significant differences between the two study groups in relation to different tissue lesions (LDH), particularly at the pulmonary (CT severity score), hepatic (AST, ALT), and muscular levels (Creatine kinase). In addition, an exacerbated procoagulant and inflammatory profile in the study group was observed. The CART algorithm approach yielded decision paths that helped sort the risk of AKI progression into three categories: the low-risk category (0–40%), the medium-risk category (40–80%), and the high-risk category (>80%). It recognized specific inflammatory and renal biomarker profiles with particular cut-off points for procalcitonin, ferritin, LDH, creatinine, initial urea, and creatinine levels as important predictive factors of AKI outcomes (93.3% overall performance). Conclusions: Our study revealed the association between particular risk factors and AKI progression in COVID-19 patients. Diabetes, dyspnea on admission, the need for supplemental oxygen, and admission to the intensive care unit all had a crucial role in producing unfavorable outcomes, with a death rate of more than 50%. Necessary imaging studies (CT scan severity score) and changes in specific biomarker levels (ferritin and C-reactive protein levels) were also noted. These factors should be further investigated in conjunction with the pathophysiological mechanisms of AKI progression in COVID-19 patients.

Background/Objectives: Several risk factors have been identified as being involved in the progression of COVID-19 over time. Among these, age, comorbidities, and various laboratory parameters have been reported. Diabetes mellitus is one of the most common comorbidities found among patients diagnosed with SARS-CoV-2 infection. Glucose metabolism dysfunction can exacerbate pre-existing diabetes or even induce diabetes mellitus. The purpose of this study is to assess the accuracy of the CURB-65, PSI, MuLBSTA severity scores and laboratory parameters in patients with diabetes mellitus diagnosed with COVID-19. Methods: We conducted a retrospective study involving patients with diabetes mellitus diagnosed with SARS-CoV-2 infection, performed between June 2023 and December 2024. Results: We analyzed 73 patients with pre-existing diabetes who were diagnosed with COVID-19. There were 56.16% men, living mostly in urban areas, with a median hospital stay of 9.38 days. Elevated levels of LDH (367.50, p = 0.002), CRP (133.90, p = 0.012), ferritin (724.25, p = 0.012), ESR (55.00, p = 0.014), D-dimers (2455.04, p = 0.004), white blood cells (12.76, p = 0.007) and the neutrophil-to-lymphocyte ratio (15.86, p = 0.021) were recorded in the group of deceased patients. Significantly elevated values were recorded for all three severity scores, the AUC for CURB-65 was 0.69, PSI 0.81 and MuLBSTA 0.86. Conclusions: Severity scores showed robust prognostic value in predicting mortality among patients with diabetes mellitus and COVID-19, emphasizing their relevance as clinically applicable tools for risk stratification and outcome assessment.